

Jiri Heracek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5968598/publications.pdf>

Version: 2024-02-01

29
papers

1,835
citations

471371

17
h-index

501076

28
g-index

32
all docs

32
docs citations

32
times ranked

2386
citing authors

#	ARTICLE	IF	CITATIONS
1	Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer. <i>New England Journal of Medicine</i> , 2009, 361, 745-755.	13.9	1,010
2	Associations of bisphenol A and polychlorinated biphenyls with spermatogenesis and steroidogenesis in two biological fluids from men attending an infertility clinic. <i>Environment International</i> , 2016, 89-90, 166-173.	4.8	119
3	Determination of selected bisphenols, parabens and estrogens in human plasma using LC-MS/MS. <i>Talanta</i> , 2017, 174, 21-28.	2.9	85
4	Development and validation of LC-MS/MS method for quantification of bisphenol A and estrogens in human plasma and seminal fluid. <i>Talanta</i> , 2015, 140, 62-67.	2.9	84
5	Enzalutamide monotherapy in hormone-naïve prostate cancer: primary analysis of an open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2014, 15, 592-600.	5.1	73
6	Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer. <i>Steroids</i> , 2007, 72, 375-380.	0.8	54
7	Serum antibodies against genitourinary infectious agents in prostate cancer and benign prostate hyperplasia patients: a case-control study. <i>BMC Cancer</i> , 2011, 11, 53.	1.1	43
8	Epigenetic regulation of transcription and splicing of syncytins, fusogenic glycoproteins of retroviral origin. <i>Nucleic Acids Research</i> , 2011, 39, 8728-8739.	6.5	40
9	Augmentation Cystoplasty in Patients with Multiple Sclerosis. <i>Urologia Internationalis</i> , 2003, 70, 21-26.	0.6	39
10	Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results. <i>European Urology</i> , 2015, 68, 787-794.	0.9	37
11	Testicular sperm aneuploidy in non-obstructive azoospermic patients. <i>Human Reproduction</i> , 2012, 27, 2233-2239.	0.4	36
12	Thirty years of research on infection and prostate cancer: No conclusive evidence for a link. A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 951-965.	0.8	33
13	HPV persistence and its oncogenic role in prostate tumors. <i>Journal of Medical Virology</i> , 2012, 84, 1636-1645.	2.5	26
14	Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results. <i>Journal of Urology</i> , 2018, 199, 459-464.	0.2	24
15	Endocrine disruptors and other inhibitors of 11 β -hydroxysteroid dehydrogenase 1 and 2: Tissue-specific consequences of enzyme inhibition. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016, 155, 207-216.	1.2	21
16	Steroids in semen, their role in spermatogenesis, and the possible impact of endocrine disruptors. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2013, 13, 1-5.	0.3	20
17	Value of power Doppler sonography with 3D reconstruction in preoperative diagnostics of extraprostatic tumor extension in clinically localized prostate cancer. <i>International Journal of Urology</i> , 2008, 15, 68-75.	0.5	19
18	Robotic Partial Nephrectomy with Indocyanine Green Fluorescence Navigation. <i>Contrast Media and Molecular Imaging</i> , 2020, 2020, 1-8.	0.4	17

#	ARTICLE	IF	CITATIONS
19	The endocrine profiles in men with localized and locally advanced prostate cancer treated with radical prostatectomy. <i>Neuroendocrinology Letters</i> , 2007, 28, 45-51.	0.2	17
20	Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2012, 15, 308-312.	2.0	13
21	A rare Robertsonian translocation rob(14;22) carrier with azoospermia, meiotic defects, and testicular sperm aneuploidy. <i>Systems Biology in Reproductive Medicine</i> , 2015, 61, 245-250.	1.0	7
22	Steroids pretreatment in assisted reproduction cycles. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014, 139, 114-121.	1.2	4
23	Enzalutamide monotherapy: Extended follow-up of a phase II study in hormone-naive prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 62-62.	0.8	4
24	Parallel optimization and genotyping of multiple single-nucleotide polymorphism markers by sample pooling approach using cycling-gradient CE with multiple injections. <i>Electrophoresis</i> , 2006, 27, 3856-3863.	1.3	3
25	Determination of Intraprostatic and Intratesticular Androgens. <i>International Journal of Molecular Sciences</i> , 2021, 22, 466.	1.8	3
26	92 TISSUE AND SERUM LEVELS OF PRINCIPAL ANDROGENS IN BENIGN PROSTATIC HYPERPLASIA AND PROSTATE CANCER. <i>European Urology Supplements</i> , 2007, 6, 45.	0.1	2
27	Indocyanine green in urological practice: recommendations and use during partial nephrectomy. <i>Urologie Pro Praxi</i> , 2021, 22, 9-12.	0.0	1
28	106 A POLYMORPHISM IN 5-ALPHA-REDUCTASE (SRD5A2) GENE SHOWS NOVEL ASSOCIATION WITH PROSTATE CANCER. <i>European Urology Supplements</i> , 2007, 6, 49.	0.1	0
29	Enzalutamide monotherapy: One-year extended follow-up of a phase 2 study in hormone-naive prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5068-5068.	0.8	0